Kornimate/medical-research-clean huggingface dataset:
pulmonary function and ct scan finding in ckd patients after covid-19 infection

Conditions: COVID-19; Lung Function Decreased; Xray Complication

Summary: covid-19 is associated with increased morbidity and mortality in patients with chronic kidney disease (ckd) on dialysis. ckd requires particular emphasis during the pandemic due to concern for increased susceptibility to infection from greater use of health facilities in people undergoing maintenance hemodialysis. covid-19 due to sars-cov-2 involves multiple organs and lung injury is one of the most clinical manifestations. the binding of sars-cov-2 to the ace2 receptors at target cells ,including type ii pneumocytes ,and alveolar macrophages in the lung could arise into acute systemic inflammatory responses and cytokine storm.the consequentially leading to lung-resident dentritic cells (rdcs) activation, t lymphocytes production and release antiviral cytokines into the alveolar septa and interstitial compartments resulting in diffuse alveolar epithelium destruction,hyaline membrane formation, alveolar septal fibrous proliferation and pulmonary fibrosis.although it has been reported that subgroups of covid-19 survivors developed persistent lung parenchymal injury that persisted at least after 6 months 5-6 ,the data in ckd patients has not been reported yet.in addition, a study of pulmonary function test after covid-19 is needed to be investigated.thus,we plan to assess pulmonary sequalae of covid-19 in hemodialysis (hd) patients and pulmonary function test after recovered of infection at least 3 months.

this is the prospective,observational cohort study including ckd stage 5 on hemodialysis who survived acute covid-19 and presented for clinical follow-up after either mild/moderate or severe covid-19.the study was conducted at faculty of medicine ,vajira hospital ,navamindradhiraj university from june 2022 -september 2022.we adhered to the declaration of helsinki,and all patients provided written informed consent before inclusion.ethics approval was obtained from institutional review board (irb) prior to start of the study (coa no 302/64 e).

Eligibility criteria:
inclusion criteria: * ckd stage 5 requiring hd or continuous peritoneal dialysis (capd ) for more than 3 months * age 18-80 years * diagnosis of covid-19 confirmed by real time polymerase chain reaction (rt-pcr) and recovered for more than3 months previously exclusion criteria: * patients with history of chronic lung diseases i.e chronic obstructive pulmonary disease (copd) and restrictive lung disease.
study evaluating safety and efficacy of moroctocog alfa (af-cc) in previously treated hemophilia a patients

Conditions: Hemophilia A

Summary: the study will be investigating pharmacokinetics, safety and efficacy in patients less than 12 years of age with severe hemophilia a that have been previously treated with factor viii products ( including blood products).


Eligibility criteria:
inclusion criteria: * male subjects less than 12 years of age with a documented history of severe hemophilia a (fviii:c less than 1%). * subjects who are less than 6 years of age must have had at least 50 exposure days (eds) to prior fviii products (including blood products). * subjects who are equal to or greater than 6 years of age must have had greater than 150 eds to prior fviii products (including blood products). exclusion criteria: * for laboratory assessments, any measured bethesda inhibitor titer equal to or greater than 0.6 bu, regardless of the laboratory normal range, or any bethesda inhibitor titer greater than uln for the testing laboratory at the time of screening. * any other bleeding disorder in addition to hemophilia a. * treatment with any investigational drug or device within 30 days before the time of signing the parental informed consent/assent form. * major surgery planned to occur during the course of the study. * regular (e.g., daily; every other day) use of agents or medications known to influence platelet function such as aspirin or certain nonsteroidal anti-inflammatory drugs (nsaids). * regular, concomitant therapy with immunomodulating drugs (e.g., intravenous immunoglobulin \[ivig\], routine systemic corticosteroids), or currently receiving immune tolerance induction (iti) for inhibitor treatment. * the subject is receiving treatment for hiv or hepatitis infection (unless the subject is on a stable antiviral regimen \[i.e., consistent treatment regimen for at least 3 months before the parental informed consent/assent form is signed\]). * platelet count less than 100,000/µl. * prothrombin time (pt) equal to or greater than 1.25 x uln, or international normalized ratio (inr) equal to or greater than 1.5. * known hypersensitivity to hamster protein.

Keywords: hemophilia a
chromium's effect on insulin resistance in obesity

Conditions: Insulin Resistance; Obesity

Summary: this research is to investigate the nutritional supplement chromium picolinate. a large number of people use chromium picolinate from health food stores to improve the function of the hormone insulin. the investigators are testing how effective this supplement is and are also monitoring its safety. in patients with diabetes, chromium has been shown to increase sensitivity to the hormone insulin. since obesity can cause insensitivity or resistance to insulin, the investigators are studying obese individuals with documented insulin resistance. the investigators would like to know if chromium is also effective in treating the insulin resistance associated with obesity.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. a bmi greater or equal to 30; and 3. an abnormal 2 hour postprandial glucose (greater than 140 mg/dl but less than 200 mg/dl) following 75 grams of a glucose load. exclusion criteria: 1. positive pregnancy test (all women must have a negative pregnancy test before beginning protocol); 2. diagnosis of cancer; 3. acute illness of any sort, however, patients may be enrolled once they are stable; 4. hemoglobin less than 11.0 g/dl or hemodynamically unstable; 5. creatinine greater than or equal to 1.5 mg/dl; 6. liver dysfunction as evidenced by elevations in transaminases 2-fold higher than upper limit of normal; 7. use of certain medications within the past month (e.g., glucocorticoids). 8. untreated hypertension (systolic bp \> 150 mmhg, diastolic bp\>ioo mmhg); 9. patients with diabetes mellitus; 10. hypogonadism; 11. abnormal thyroid function (serum t4 \ 12; tsh \ 5.5) (12) any chronic liver or kidney disease; or 12. polycystic ovarian syndrome.

Keywords: chromium picolinate insulin resistance obesity
experience of parents/carers of children with severe motor disabilities suffering from spinal pain?

Conditions: Low Back Pain

Summary: parents of disabled children suffer from back pain more frequently than the general population. at present, the literature does not identify any specific factors responsible for this suffering. for patients suffering from chronic back pain, there are specific treatment programmes in the physical medicine and rehabilitation department, with a focus on pain management. the investigators would like to develop specific programmes for parents/carers of children/adolescents with severe motor disabilities. to achieve this, it is important to gain a better understanding of the factors that contribute to the onset of pain. with this in mind, the investigators are conducting a qualitative study to gain a better understanding of the day-to-day lives of these parents.


Eligibility criteria:
inclusion criteria: * parents or carers of children with severe motor disabilities complaining of spinal pain exclusion criteria: * parent/carer refusing to participate
oral dexamethasone as an intervention for postoperative pain and nausea management in total knee arthroplasty

Conditions: Arthritis Knee; Postoperative Nausea; Postoperative Pain

Summary: this study aims to determine if oral dexamethasone provides clinically significant improvement in postoperative outcomes, specifically nausea and pain scores.

protocols in perioperative pain management during total joint arthroplasty (tja) have contributed to early discharge after surgery. as practices move to favor ambulatory surgery in total joint arthroplasty changes must be made to postoperative pain and nausea management. spinal anesthesia has been essential in managing associated ambulatory tja, however, nausea and vomiting are known detrimental side effects. the use of systemic steroids has also been shown in the literature to reduce pain scores, length of stay, the need for antiemetics, and increase the distance of ambulation without increasing the rate of surgical site infection or prosthetic joint infection. as more same-day total joint replacement is incorporated into practice, an oral alternative may prove beneficial.

Eligibility criteria:
inclusion criteria: * adult patients age 18 and older who will be undergoing joint replacement exclusion criteria: * patients with uncontrolled diabetes ( hba1c, \>7.5%), impaired hepatic function (child class, \>b), impaired renal failure (glomerular filtration rate \<60 ml/min/1.73 m2), chronic narcotic use, alcohol and/or opioid dependence, patients with a known adverse reaction to corticosteroids, and patients unable to give informed consent.
pkp assisted with mr technology in ovcf with ivc

Conditions: Orthopedic Disorder of Spine

Summary: to prospectively assess the outcome of pkp assisted with and without mr technology in treatment of ovcf with ivc.

the study is to prospectively assess the outcome of pkp assisted with and without mr technology in treatment of ovcf with ivc. forty cases of ovcf with ivc undergoing pkp were randomized into a mr technology assisted group (group a) and a traditional c-arm fluoroscopy group (group b). both groups were performed pkp and evaluated by vas scores, odi scores, radiological evidence of vertebral body height and kyphotic angle(ka) at pre-operation and post-operation. the volume of injected cement and operation time was recorded. and whether cement touching both endplates or not(non-pmma-endplates-contact, npec) in radiological evidence were also recorded postoperatively. the clinical outcomes and complications were evaluated afterwards. all patients received 10 to 14 months' follow-up, with an average of 12 months.

Eligibility criteria:
inclusion criteria: * single level ovcf in the thoracic and lumbar levels (t10-l4), suffering with severe back pain.; * ovcf without damaged vertebral posterior wall and nerve lesion; * the patient was over 50 years old and , the diagnosis of osteopenia or osteoporosis was confirmed by bone densitometry ; * all patients underwent（received） plain radiography, computed tomography (ct) and mri before surgery, and with ivc presented in mri. exclusion criteria: -
patient-centered collaborative care for preventing post-traumatic stress disorder after traumatic injury

Conditions: Post-Traumatic Stress Disorder

Summary: this study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury.

approximately 2.5 million people in the u.s. are hospitalized each year having sustained injuries during a traumatic event. injured trauma survivors are at high risk for developing post-traumatic stress disorder (ptsd) and other related conditions. in addition, many of these people experience several physical, financial, social, legal, and medical problems over the course of the year following the trauma. effective interventions to prevent or remedy these issues have yet to be developed for individuals who undergo inpatient surgery following a traumatic injury and who then continue with outpatient treatment and community rehabilitation. this study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of ptsd and substance use. the study will also assess the intervention's effectiveness in increasing participants' general functioning and satisfaction with their care post-injury. participants in this open label study will be randomly assigned to receive either the standard care provided to injured trauma survivors or a combination of behavioral therapy and drug therapy. participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline; paroxetine; buspirone; propranolol; trazodone; and any of the benzodiazepines. participants may begin receiving medication immediately or anytime within the 12 months post-injury. behavioral therapy will also be administered on the basis of the participants' individual needs and may continue for up to 12 months. participants will also take part in motivational interviews, the first of which will be conducted upon study entry in the hospital ward. subsequent interviews will be conducted over the phone at months 1, 3, 6, 9, and 12. participants will be required to report to the study site only for the initial baseline visit. outcome measures will include ptsd severity ratings, frequency of substance use, and general functioning reports.

Eligibility criteria:
inclusion criteria: * english-speaking * admitted to harborview medical center with injuries sufficiently severe to require inpatient admission * experienced a traumatic injury * exhibits symptoms of ptsd while in the hospital ward exclusion criteria: * history of head, spinal, or other injury that may prevent participation in the ward interview * requires immediate intervention due to conditions such as self-inflicted injury, active psychosis, or active mania * currently incarcerated * likely to face criminal charges * lives more than 50-100 miles from harborview medical center

Keywords: ptsd
weight loss maintenance and compensatory mechanisms activated with a very-low calorie diet

Conditions: Obesity, Morbid

Summary: very-low calorie diets are relatively safe and effective in inducing significant weight loss, when used in selective individuals and under clinical supervision. however, weight loss maintenance in the long-term remains the main challenge, with many experiencing a significant weight regain. several compensatory mechanisms are activated under weight reduction, both at the level of energy intake (such as increased appetite) and energy expenditure (such as reduced energy expenditure), and increase the risk of relapse. the main aim of this study is to compare the effect of two multidisciplinary lifestyle interventions on weight loss maintenance at one year, after initial weight loss during 8 weeks very-low calorie diet. participants will be allocated (non-randomly) to either an outpatient program in the obesity unit of the local hospital, or to an inpatient program consisting of a "continuous care" intervention, with three intermittent stays (each with three-week duration) in a rehabilitation center over a one year period. moreover, the investigators aim to assess the impact of weight loss (achieved with a very low calorie diet) and weight loss maintenance on compensatory mechanisms activated during weight reduction.

this study included a sub-study (n=30) to determine the timeline over which compensatory mechanisms (at both the level of energy expenditure and appetite control system) are activated with progressive weight loss. additional measurements were taken at day-3, 5 and 10 % weight loss, and after 4 weeks weight stabilization (after gradually reintroduction of food).

Eligibility criteria:
inclusion criteria: * volunteers from central norway * if female: taking oral contraceptives or post-menopausal * body mass index 30-45 kg/m2 * stable weight (\<2kg variation in the last 3 months) * not currently dieting to lose weight exclusion criteria: * pregnancy * breast feeding * drug or alcohol abuse within the last two years * current medication known to affect appetite or induce weight loss * enrollment in another obesity treatment program * history of psychological disorders * history of eating disorders * history of diabetes type 1 or 2 * gastrointestinal disorders (particular cholelithiasis) * kidney -, liver -, lung- or cardiovascular disease * malignancies

Keywords: weight reduction programs diet caloric restriction weight loss weight gain
bawei shenqi pill in the treatment of ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the purpose of this study is to determine whether bawei shenqi pill is effective in the treatment of active ankylosing spondylitis (as).

ankylosing spondylitis is a chronic inflammatory disease, which mainly invades sacroiliac joint, spinal osteoid process, paraspinal soft tissue and peripheral joints, and can be accompanied by extraarticular manifestations, in severe cases, spinal deformity and ankylosis can occur. the overall prevalence rate of ankylosing spondylitis in china is about 0.3%, the peak of which is 20 to 30 years old. although the prevalence rate is not high, the disability rate is high, and the patients with ankylosing spondylitis are mainly young people of childbearing age, which are in a critical period of work and study. if the disease can not be controlled smoothly, it will seriously affect its learning and work efficiency, image appearance and even the ability of daily life. bawei shenqi pill originates from zhang zhongjing's synopsis of the golden chamber, is the representative prescription of warming and tonifying kidney yang, and is also suitable for the pathogenesis of ankylosing spondylitis "deficiency of kidney yang". the purpose of this study was to observe the therapeutic effect of bawei shenqi pill on ankylosing spondylitis of kidney-yang deficiency type through a randomized controlled clinical study. to clarify the effect of bawei shenqi pill on disease activity, joint function, tcm syndrome integral and quality of life in patients with ankylosing spondylitis, and to provide basis for the treatment of ankylosing spondylitis with bawei shenqi pill.

Eligibility criteria:
inclusion criteria: * compliance with new york standards revised in 1984 * syndrome differentiation of traditional chinese medicine for deficiency of kidney-yang * 18 to 70 years of age, male and female * being able to understand or sign an informed consent form exclusion criteria: * other spondyloarthropathy that does not meet the diagnostic criteria of ankylosing spondylitis, and tcm syndrome differentiation does not belong to kidney-yang deficiency type. * age is out of range * do not agree to participate in this topic or can not participate in the whole process * complicated with other rheumatic diseases or other seronegative spondyloarthropathy. * pregnant, lactating women and patients with serious visceral diseases, mental disorders and severe extraarticular manifestations, such as heart, lung, liver, kidney or hematopoietic system. * have had myocardial infarction or stroke, congestive heart failure and active digestive tract ulcer patients. * those who had received other research drugs three months before screening. * inability or unwillingness to provide informed consent or failure to comply with test requirements. * the researchers believe that it is not suitable for the owners of the study.

Keywords: bawei shenqi pill ankylosing spondylitis clinical research
kinetics of circulating tumoral cells in bronchial primitive cancer

Conditions: Bronchial Cancer

Summary: the pronostic value of circulating tumoral cells(ctc) 's dosage by the method iset® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated. however, no kinetic study was ever realized to study the value of the ctc as predictive indicator of answer to the therapy. this project plans to study patients in an early stage and patients at advance stage locally moved forward or metastatic of the disease by evaluation of the presence and the number of ctc before every cure. this collaborative and original study should allow to refine the diagnoses of answer and to plan the possible relapses what would allow a premature institution of the treatment.


Eligibility criteria:
inclusion criteria: * patients with non-small cell lung cancer * accepting participation exclusion criteria: * refusing participation
messages and plans to increase gym utilization

Conditions: Body Weight

Summary: this primary object of this study is to test to the hypothesis that the both the nudge and boost messages will increase short term gym utilization relative to the control condition but that only the boost message will increase long-term gym utilization. non-technical summary: college students will receive one of three messages about exercise. their card swipe data as a measure of gym utilization will be tracked as an assessment of the effect of those messages.

our study uses a survey methodology. within the survey, participants are randomly assigned to experimental conditions. after completion of the survey, participants' real-world behavior is assessed via gym card swipe data. within the survey, an experimental quantitative three group design will be used to answer our research question. thus, our independent variable has three levels: the control message, the nudge message, and the boost message. our dependent variable will be collected gym card swipes over the semester. the three experimental message conditions will be delivered within the questionnaire that participants complete. the control group will read only summary information about the david pottruck health and fitness center. participants in the nudge condition will read a similar summary but will also be given a prompt to form an implementation intention. those in the boost condition will also have summary information about the pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. they will also be given a prompt to form an implementation intention.

Eligibility criteria:
inclusion criteria: * must be undergraduates at the university of pennsylvania exclusion criteria: * n/a
neuromuscular electrical stimulation (nmes) for dysphagia in neonates

Conditions: Dysphagia

Summary: the purpose of this study is to evaluate if the use of neuromuscular electrical stimulation (nmes) will provide a more efficient method of treating neonates with dysfunctional oral feeding such as dysphagia. this study will attempt to determine if nmes applied to neonates at 36-42 weeks post-conception age (pca) will decrease the need for nasogastric tubes (ng) and gastrostomy tubes (g-tube). increase the rate at which these neonates complete full oral feeds, improve their swallowing skills, increase oral intake of calories, and gain weight.


Eligibility criteria:
inclusion criteria: * male or female. * meet diagnostic criteria for dysphagia symptoms using the nomas and a vfss. * infants with intraventricular hemorrhage (ivh) and hypoxic events can be included. * infants taking less than 5-10% of target volume by mouth between the ages of 36-42 weeks pca. * multiple swallows to clear bolus following suck that includes a desaturation \<80% and bradycardia \<80 bpm. * apnea spells during feeds. * aspiration or penetration by vfss exclusion criteria: * known neurologic or neurodegenerative disorders. * chromosomal anomalies and syndromes. * cleft lip or palate. * birth defects. * unresolved cutaneous rash at the area of electrode placement. * medical condition that is a contraindication to nmes.

Keywords: dysphagia neuromuscular electrical stimulation nmes neonates vitalstim